Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
November 05 2020 - 9:29AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP)
(Cyclacel or the Company), a biopharmaceutical company developing
innovative medicines based on cancer cell biology, will announce
third quarter 2020 financial results on Wednesday, November
11, 2020. The Company will host a conference call and live webcast
at 4:30 p.m. Eastern Daylight Time on the same day.
Conference call
information:
US/Canada call: (877) 493-9121 /
international call: (973) 582-2750
US/Canada archive: (800) 585-8367 /
international archive: (404) 537-3406
Code for live and archived conference call is
4884678.
For the live and archived webcast, please visit
the Corporate Presentations page on the Cyclacel website
at www.cyclacel.com. The webcast will be archived for 90 days
and the audio replay for 7 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company developing innovative cancer medicines
based on cell cycle, transcriptional regulation, and DNA damage
response biology. The transcriptional regulation program is
evaluating fadraciclib as a single-agent in solid tumors and in
combination with venetoclax in patients with relapsed or refractory
AML/MDS and CLL. The anti-mitotic program is evaluating CYC140, a
PLK1 inhibitor, in advanced leukemias/MDS patients. The DNA damage
response program is evaluating an oral combination of sapacitabine
and venetoclax in patients with relapsed or refractory AML/MDS. An
investigator-sponsored trial (IST) is evaluating an oral
combination of sapacitabine and olaparib in patients with BRCA
mutant breast cancer. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused on hematology and oncology based
on a pipeline of novel drug candidates. For additional information,
please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy,
safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings Cyclacel files with
the Securities and Exchange Commission which are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and Cyclacel assumes no obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts
Company: |
Paul McBarron,
(908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Russo Partners LLC, Eric Ando, (646) 218-4604,
eric.ando@russopartnersllc.com |
© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All
Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2023 to Apr 2024